NFKB1 and diffuse large B-cell lymphoma: The biology revealed by c-Rel GEP signatures from this study has gained insight into the NF-κB pathways providing important information for further functional study, and suggest that therapeutic approaches targeting BCR, cell cycle, cytokine, and the p53 pathway, as well as BET inhibitors, but not proteasome inhibitors, may have clinical benefits in c-Rel+ DLBCL patients.